Skip to main content
ViroGates A/S logo

ViroGates A/S — Investor Relations & Filings

Ticker · VIRO ISIN · DK0061030574 LEI · 5493007TX8XS56RMZD94 ST Manufacturing
Open in API
Filings indexed 162 across all filing types
Latest filing 2022-07-15 Director's Dealing
Country DK Denmark
Listing ST VIRO

About ViroGates A/S

https://www.virogates.com/

ViroGates A/S is an in-vitro diagnostics company that develops and markets blood tests to measure chronic inflammation. The company's core product line, suPARnostic®, is based on the suPAR (soluble urokinase Plasminogen Activator Receptor) biomarker. This biomarker measures the activation level of the immune system to predict patient outcomes, disease risk, and the severity of chronic inflammation. The primary applications for suPARnostic® products are in hospitals for patient triaging, in the longevity market for health assessment, and in clinical research. The technology aims to improve patient care, optimize resource allocation in healthcare settings, and advance inflammation-based diagnostics.

Recent filings

Filing Released Lang Actions
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
Director's Dealing Classification · 100% confidence The document is a standard regulatory form used in Denmark (Finanstilsynet) to report transactions by persons discharging managerial responsibilities (PDMRs). It explicitly lists the name of the executive (Jakob Knudsen), the issuer (ViroGates A/S), the nature of the transaction (Køb/Purchase of shares), and the price/volume details. This falls under the category of Director's Dealing (insider trading notification).
2022-07-15 Danish
ViroGates notification of transactions by persons discharging managerial responsibilities according to MAR art. 19
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (PDMR), specifically the CEO, Jakob Knudsen, as required by MAR (Market Abuse Regulation) Article 19. It details the purchase of shares, including the price, quantity, and date of the transaction. This falls directly under the definition of 'Director's Dealing' (DIRS).
2022-07-15 English
ViroGates announces the final outcome of its rights issue
Share Issue/Capital Change Classification · 100% confidence The document is a company announcement detailing the final outcome of a rights issue (a capital raising event). It specifies the number of shares subscribed, the amount of capital raised, and the impact on the company's share capital. This falls directly under the definition of a share issue or capital change announcement.
2022-07-08 English
ViroGates announces the final outcome of its rights issue
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement regarding the final outcome of a rights issue (a capital raising event). It details the number of shares subscribed, the amount of capital raised, and the impact on the company's share capital. While it mentions an attached PDF, the text itself provides the substantive details of the transaction, making it a primary announcement of a capital change/financing activity rather than just a notification of a report's availability. Therefore, it fits best under the 'Share Issue/Capital Change' category.
2022-07-08 English
ViroGates announces a capital increase in connection with the exercise of warrants and grant of warrants to members of the non-executive board of directors
Share Issue/Capital Change Classification · 100% confidence The document is a formal company announcement from ViroGates A/S regarding a capital increase resulting from the exercise of warrants and the issuance of new warrants to board members. It details the number of shares issued, the proceeds, and the impact on the company's total share capital. This falls under the category of share issuance and capital structure changes.
2022-07-07 English
ViroGates announces a capital increase in connection with the exercise of warrants and grant of warrants to members of the non-executive board of directors
Share Issue/Capital Change Classification · 95% confidence The document is a company announcement from ViroGates detailing a capital increase resulting from the exercise of warrants and the issuance of new warrants to board members. This falls under the category of share issuance and capital structure changes. While it mentions an attachment, the document itself contains the full details of the transaction, making it a primary filing rather than just a notification of a report.
2022-07-07 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.